Syntex (u.s.a.) Inc.

Hoffmann-la Roche Inc.

Syntex LLC

John J Nestor

Brian H Vickery

Gordon H Jones

John G Moffatt

Hans Maag

Hardy W Chan

Milan R Uskokovic

Pamela M Burton

Alain B Schreiber

Scott William Womble

Abraham White, Deceased

John M Sims

The L-monovaline ester derived from 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol and its pharmaceutically acceptable salts are of value as antiviral agents with improved absorption.

2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol

2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol

A method for treating osteoporosis via administration of a compound of the formula, 1.alpha.-fluoro-25-hydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol, in an amount therapeutically effective to restore bone density to an asymptomatic level, without inducing hypercalciuria, hypercalcemia, or nephrotoxicity is provided.

Method for treating osteoporosis

The present invention relates to novel synthetic antigens, conjugates and antibodies based upon specific peptide sequences and the production thereof. More particularly, the invention relates to a polypeptide which is a determinant site of a protein, the polypeptide having from 8 to 20 amino acid residues, having an amino-terminal amino acid and a carboxyl-terminal amino acid, wherein the polypeptide includes:

Synthetic peptide sequences useful in biological and pharmaceutical

Synthetic nona- and decapeptide LHRH antagonist analogs are disclosed, having a sterically hindered guanidino-substituted arginyl or homoarginyl residue at position 8, with no arginyl substituent at position 6.

Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists

N',N'-dialkylguanidino dipeptides with angiotension converting enzyme (ACE) inhibiting activity are useful as antihypertensives. Proline and proline analogs are components of the dipeptides.

N',N'-dialkylguanidino dipeptides

.alpha.-amino acids having a substituted .omega.-guanidino group are disclosed herein.

.omega.-Guanidino-substituted-.alpha.-amino acids

Synthetic nonapeptide and decapeptide LHRH antagonist analogues having a halo lower alkyl guanadino-substituted amino acyl residue at position six are disclosed herein.

Nona and decapeptide analogs of LHRH useful as LHRH antagonists

Polypeptides analogs of fragments of TGF.alpha. and EGF are useful as therapeutic and diagnostic agents.

Analogs of transforming and epidermal growth factor fragments for

Synthetic nonpeptide and decapeptide LHRH antagonist analogs have a novel guanido-substituted, amidine, tertiary or quaternary amine water-soluble aminoacyl residue at position 6.

Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists

Peptides which promote the release of growth hormone by the pituitary gland or which inhibit the release of growth hormone by growth hormone releasing factor and which have an N,N'-dialkyl substituted guanidino amino acyl residue at position 1 or 2 are disclosed herein.

N,N'-dialkyl substituted guanidino amino acyl residue substituted

Synthetic nona-peptide and deca-peptide LHRH antagonist analogs have a novel guanido-substituted, amidine, tertiary or quaternary aminoacyl residue at position 6.

Nona-peptide and deca-peptide analogs of LHRH, useful as LHRH antagonists

Synthetic nonapeptide and decapeptide LHRH agonists analogs having a novel gaunadino-substituted, amidine, tertiary or quatrinary aminoacyl residue at position 6 are disclosed herein.

Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist

Nonapeptide and decapeptide analogs of LHRH which have the formula ##STR1## and the pharmaceutically acceptable salts thereof.

Growing community of inventors

San Jose, CA, United States of America

John J Nestor